Among the CTAs identified in colorectal cancer, NY-ESO-1, MAGE-A, LAGE-1, OIP5, TTK, PLU1, DKKL1, and FBXO39 are highly expressed, making them promising targets for immunotherapy (9). This evidence concerns the gene FBXO39 and colorectal cancer.